On December 19, 2025, Cytokinetics, Inc. reported that the FDA approved MYQORZO™ (aficamten) for treating symptomatic obstructive hypertrophic cardiomyopathy in adults. This approval allows the use of MYQORZO in 5 mg, 10 mg, 15 mg, and 20 mg tablets to improve patients' functional capacity and symptoms.